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Editorial Article 
Public Health Pharmacogenomics and the Design Principles for Global 
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“Evidence in the clinical care context differs from evidence in the public health and health policy domains. It is often difficult 
to apply rigid hierarchies of evidence to public health policy.”  
Tikki Pang [1]
“Pharmacogenomics and personalized medicine knowledge cannot be siloed into a pure and narrow technology lens alone. 
The field’s ontology requires a nuanced understanding of the complex linkages between the science, technology, society, and 
politics ecosystem and therefore must be situated within a broader framework.” 
Edward S. Dove [2]
“The trend has been to use data derived from African populations to build research programmes and enhance individual 
careers in more affluent communities with little or no consideration for the populations from which this material was derived.” 
Jantina de Vries and Michael Pepper [3]
1. A POPULATION FOCUS FOR GENOMICS, PER- 
SONALIZED MEDICINE AND GLOBAL SOCIETY 
Current Pharmacogenomics and Personalized Medicine 
(CPPM) was launched in 2008 to respond to knowledge, 
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policy and biotechnology governance gaps at the unique 
intersection of personalized medicine, genomics, public 
health and social studies of knowledge-based innovation. 
Distinct from traditional discovery science characterized by a 
“first hypothesize-then-experiment” method of scientific 
inquiry, this nascent field of public health pharmacogenomics 
is richly informed by CPPM scholarship that recognizes the 
new dual reconfiguration of 21st-century data-intensive 
omics science, blending infrastructure science and discovery 
science. Importantly, CPPM addresses novel diagnostics and 
responsible personalized medicine applications both in 
developing and developed countries. This is crucial for 
global capacity building, as developing countries may 
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lack the resources, expertise and sound regulation for 
pharmacogenomics; this may result in premature buy-in for 
novel biotechnologies without adequate alignment with local 
public health priorities and societal values [3, 4]. 
The journal aims to strike the right balance to catalyze 
the transition of pharmacogenomics and personalized 
medicine discoveries to practice, while preventing the 
premature translation of candidate applications [5-7]. 
Finally, the journal integrates molecular and clinical 
investigation with public policy and social studies of 
biotechnology, which collectively shape the postgenomics 
personalized medicine innovation trajectory.  
2. LOOKING BEYOND THE LABORATORY SPACE:
RESPONSIBLE INNOVATION 
“Responsible innovation” is an emerging concept that 
CPPM scholars investigate, and is closely linked to public 
health pharmacogenomics. For innovation to be responsible, 
the scientific design space must involve more than traditional 
experts. It must involve a broad array of experienced, 
engaged and enthusiastic members of the public, such as 
citizen scholars, patients, policymakers and other knowledge 
end-users [5-10]. This “opening up” of the hitherto cloistered 
scientific design space produces scientific knowledge that is 
closely embedded with societal values, the public interest 
and end-user priorities and thus, becomes socially robust and 
sustainable.  
Just as public health pharmacogenomic needs input from 
a broader, large range of publics, so too does it require access 
to large information databases and adequate knowledge 
translation platforms that facilitate knowledge synthesis and 
dissemination across experts and publics. The powerful 
scope of this field will be fully realized once genomic 
population-based studies can be effectively linked to 
population-based health administrative databases, electronic 
health records, and nutrition and lifestyle data. This has 
significant societal, legal and ethical implications, in terms 
of confidentiality and privacy of individuals contributing 
genomic data, not to mention the new ways of understanding 
these constructs in the age of post-genomics personalized 
medicine [11]. This will require profound deliberation and 
input from those involved in policy development. As it has 
done for the last five years, CPPM will continue to lead the 
way in co-creating and disseminating policy relevant scientific 
advances to sustain public trust in pharmacogenomics and 
public health. 
Public health pharmacogenomics also offers the promise 
to prevent research waste, which remains a serious problem 
in the health domain. For example, a scoping analysis of 344 
studies in health and allied sciences addressing patients’, 
clinicians’ and researchers’ priorities for research, found that 
only nine considered the extent to which questions posed by 
researchers matched questions of relevance to patients and 
clinicians [12]. Furthermore, translation of pharmacogenomics 
into the clinic remains a challenge, especially in low and 
middle income countries that can benefit much from 
effective and safe therapeutic regimes [13].  
CPPM’s focus on public health pharmacogenomics is 
aligned with integrated, responsible innovation, knowledge 
co-production and benefit-sharing by scientists, technology 
designers, communities and other producers or consumers of 
knowledge. As noted earlier by Dove in this journal [2], this 
in part reflects the journal’s commitment to horizontalization 
of knowledge co-production: it is not a question of the 
contributors’ age, gender, geographical location, perceived 
prestige of authors’ institutional affiliation, maiden language, 
individual social capital or economic power, but rather one 
of original, reasoned ideas and scholarship. We posit that a 
good amount of research waste can be eliminated if researchers 
and patients, participants and publics communicated with, 
rather than past, one another and consider viewpoints from 
all peoples and places, especially given the often serendipitous 
nature of scientific and technological discovery and 
development. Ultimately, such nonassuming horizontal 
approach to knowledge co-production helps create an open 
commons that is self-corrective and self-calibrating against 
biases, entrenched politics and disciplinary or epistemic 
“knowledge tribes” created by human kinds, and embedded 
in human positivist inquiry, be it in natural sciences, social 
sciences or humanities [4, 9]. 
3. DESIGN PRINCIPLES FOR GLOBAL PUBLIC
GOODS 
We have started the current socio-technical analysis of 
the post-genomics personalized medicine landscape with 
quotes from scholars in global public health and social 
studies of biotechnology and innovation, including Tikki 
Pang, the lead writer of the World Health Report 2012. Pang 
has recently suggested to us that the future developers and 
users of diagnostics for health interventions (theranostics) to 
be cognizant of the “design principles” for global public 
goods (GPGs), of which public health pharmacogenomics is 
a good example. These principles were outlined by Elinor 
Ostrom, Nobel Laureate in Economic Sciences in 2009 
(Table 1, with modifications by Pang) [14, 15]. CPPM
readers are encouraged to read the seminal works on the 
governance of the commons and institutional diversity by 
Ostrom [15, 16], and the ways in which these can impact 
behavior in society, including our 21
st
 century knowledge
society [8] that is being shaped by globalization of genomics 
and personalized medicine [5, 11, 13]. 
4. WHAT IS NEXT FOR PUBLIC HEALTH PHARMA- 
COGENOMICS? 
We are situating this first issue of the new year, and 
reaffirming the commitment of CPPM, to address the needs 
of the personalized medicine knowledge society [8, 17-22]. 
We are also commencing the new year with an expanded, 
globally inclusive, distributed and transdisciplinary 
international editorial board. CPPM senior editorial 
leadership will transition and evolve in the coming months to 
further accelerate this progressive vision that has brought to 
light cutting edge research, and transformative ideas in 
pharmacogenomics and personalized medicine over the past 
five years by leading scholars from all parts of the 
globe (see, for example, [13, 21-24]). In this inclusive spirit, 
we welcome your enthusiastic contributions of manuscripts 
for peer review in 2013 and beyond.  
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